FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including the use of a molecule of an antibody against PD-1 in the treatment of cancer in a subject (options), a method for the treatment of cancer in a subject (options), the use of a pharmaceutical composition including a molecule of an antibody against PD-1, at a dose from about 300 mg to 400 mg once every three weeks or once every four weeks, for the treatment of cancer. In one of options of implementation, a molecule of an antibody against PD-1 is used in the treatment of cancer at a dose from about 300 mg to 400 mg once every three weeks or once every four weeks.
EFFECT: invention expands the arsenal of methods for the treatment of cancer, using a molecule of an antibody against PD-1.
103 cl, 35 dwg, 13 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| 5-BROMO-2,6-DI - (1H-PYRAZOL-1-YL)PYRIMIDINE-4-AMINE FOR USE IN CANCER TREATMENT | 2016 |
|
RU2745560C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| DOSING REGIMEN OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN A COMBINATION | 2018 |
|
RU2767533C2 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| 1-(4-AMINO-5-BROMO-6-(1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)-1H-PYRAZOL-4-OL AND ITS APPLICATIONS FOR CANCER TREATMENT | 2018 |
|
RU2791531C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
